Inactive Instrument

Impax Laboratories Inc Stock Nasdaq

Equities

US45256B1017

Pharmaceuticals

Sales 2024 * 2.62B Sales 2025 * 2.75B Capitalization 2.09B
Net income 2024 * -84M Net income 2025 * 23M EV / Sales 2024 * 1.67 x
Net Debt 2024 * 2.3B Net Debt 2025 * 2.09B EV / Sales 2025 * 1.52 x
P/E ratio 2024 *
-25 x
P/E ratio 2025 *
96.6 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 26.94%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder 57 01-12-31
Founder 53 01-12-31
Director of Finance/CFO 57 Nov. 06
Members of the board TitleAgeSince
Director/Board Member 66 Nov. 06
Director/Board Member 69 Nov. 06
Chairman 71 Nov. 06
More insiders
Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.
Related indices
More about the company